Evaluation of resistance to low pH and bile salts of human Lactobacillus spp. isolates
Open Access
- 27 July 2015
- journal article
- research article
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 28 (3), 426-433
- https://doi.org/10.1177/0394632015590948
Abstract
There are nearly 100 trillion bacteria in the intestine that together form the intestinal microbiota. They are ‘good’ bacteria because they help to maintain a physiological balance and are called probiotics. Probiotics must have some important characteristics: be safe for humans, be resistant to the low pH in the stomach, as well as bile salts and pancreatic juice. Indeed, their survival is the most important factor, so that they can arrive alive in the intestine and are able to form colonies, at least temporarily. The aim of our study was the evaluation of resistance of Lactobacillus isolates from fecal and oral swabs compared to that found in a commercial product. Seven strains were randomly chosen: L. jensenii, L. gasseri, L. salivarius, L. fermentum, L. rhamnosus, L. crispatus, and L. delbrueckii. We observed a large variability in the results: L. gasseri and L. fermentum were the most resistance to low pH, while only L. gasseri showed the best survival rate to bile salts. Interestingly, the commercial product did not show tolerance to both low pH and bile salts.Keywords
This publication has 23 references indexed in Scilit:
- Scientific Opinion on the substantiation of health claims related to Lactobacillus fermentum CECT5716 and maintenance of the upper respiratory tract defence against pathogens by maintaining immune defences (ID 916) pursuant to Article 13(1) of RegulationEFSA Journal, 2010
- Scientific Opinion on the substantiation of a health claim related to Lactobacillus casei strain Shirota and maintenance of the upper respiratory tract defence against pathogens by maintaining immune defences pursuant to Article 13(5) of Regulation (EC) NEFSA Journal, 2010
- Scientific Opinion on the substantiation of health claims related to Lactobacillus rhamnosus LB21 NCIMB 40564 and decreasing potentially pathogenic intestinal microorganisms (ID 1064), digestive health (ID 1064), and reduction of mutans streptococci in the oral cavity (ID 1064) pursuant to Article 13(1) of Regulation (EC) No 1924/2006EFSA Journal, 2010
- Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic‐associated diarrhoea in childrenAlimentary Pharmacology & Therapeutics, 2008
- Saccharomyces boulardii Inhibits ERK1/2 Mitogen-activated Protein Kinase Activation Both in Vitro and in Vivo and Protects against Clostridium difficile Toxin A-induced EnteritisJournal of Biological Chemistry, 2006
- Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogensFEMS Microbiology Reviews, 2004
- Bacterial composition of commercial probiotic products as evaluated by PCR-DGGE analysisInternational Journal of Food Microbiology, 2002
- The Lactic Acid Bacteria: A Literature SurveyCritical Reviews in Microbiology, 2002
- Probiotics: “living drugs”American Journal of Health-System Pharmacy, 2001
- Lactic Acid Permeabilizes Gram-Negative Bacteria by Disrupting the Outer MembraneApplied and Environmental Microbiology, 2000